Table 1 Clinical and sampling profiles of patients studied.
Patient | HLA class I type | Time of last HIV Ab negative test (DFOSx1) | Time of first fully positive HIV Ab test (DFOSx) | First sampling time-point studied (DFOSx) | Viral load at first PBMC sampling time point (RNA copies/ml plasma) | Setpoint persisting viral load established after the acute phase of infection (RNA copies/ml plasma) | ||
|---|---|---|---|---|---|---|---|---|
MM7 | A*02 A*03 | B*07 B*44 | Cw*05 Cw*07 | Evolving at 11 | 16 | 23 | 690,000 | 128,925 |
MM9 | A*01 A*66 | B*41 B*08 | Cw*07 Cw*07 | 7 | 19 | 19 | 142,700 | 19,379 |
MM12 | A*03 A*68 | B*07 B*44 | Cw*07 Cw*07 | ND2 | 7 | 16 | 1,555,700 | 97,970 |
MM13 | A*01 A*01 | B*08 B*57 | Cw*06 Cw*07 | ND | 15 | 16 | 131,800 | 15,348 |
MM26 | A*02 A*68 | B*51 B*35 | Cw)15 Cw*04 | Evolving at 37 | 49 | 55 | 56,200 | 34,493 |
MM27 | A*02 A*03 | B*07 B*44 | Cw*05 Cw*07 | Evolving at 12 | 26 | 28 | 353,200 | 48,360 |
MM28 | A*11 A*30 | B*13 B*35 | Cw*04 Cw*06 | 6 | 9 | 6 | 4,337,100 | 12,322 |
MM33 | A*02 A*68 | B*07 B*44 | Cw*05 Cw*07 | Evolving at 9 | 12 | 12 | 1,451,400 | 73,958 |
MM34 | A*01 A*24 | B*51 B*35 | Cw*12 Cw*12 | Evolving at 10 | 17 | 17 | 29,900 | 8,522 |
MM39 | A*02 A*03 | B*15 B*35 | Cw*03 Cw*04 | Evolving at 3 | 23 | 5 | 350,600 | 8,546 |
MM43 | A*02 A*02 | B*55 B*40 | Cw*10 Cw*09 | Evolving at 6 | 13 | 21 | Not available (898,100 at 27 DFOSx) | 64,565 |
MM45 | A*03 A*03 | B*07 B*51 | Cw*07 Cw*15 | Evolving at 1 | 22 | 22 | 23,200 | 1,917 |
MM46 | A*02 A*11 | B*08 B*52 | Cw*07 Cw*12 | 1 | 5 | 5 | 224,100 | 81,011 |
MM47 | A*24 A*24 | B*39 B*65 | Cw*02 Cw*07 | Evolving at -1 | 8 | 28 | 17,000 | 15,839 |
MM48 | A*24 A*26 | B*62 B*27 | Cw*01 Cw*09 | 1 | Evolving at 16 | 22 | 40,100 | 4,266 |
MM51 | A*02 A*30 | B*13 B*44 | Cw*05 Cw*06 | Evolving at 5 | 39 | 18 | 39,400 | 26,557 |
MM55 | A*01 A*33 | B*14 B*15 | Cw*07 Cw*08 | 6 | 24 | 31 | 1,200 | 50 |
MM56 | A*02 A*24 | B*35 B*57 | Cw*04 Cw*06 | 4 | ND | 14 | 15,000 | 1,023 |